PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
13.58
Current Ratio above 1.5x Biotechnology median of 5.69. Joel Greenblatt would see extra liquidity as a cushion for downturns.
13.58
Quick Ratio above 1.5x Biotechnology median of 5.54. Joel Greenblatt would see a superior short-term safety net.
13.39
Cash Ratio above 1.5x Biotechnology median of 2.79. Joel Greenblatt might see a strategic advantage in crisis periods.
-30.15
Negative interest coverage while Biotechnology median is -6.90. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
-14.65
Negative short-term coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize cash flow quality and look for immediate refinancing solutions.